help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DRAZEN, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DRAZEN, J.

Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, S233-S237

Clinical Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors

JEFFREY DRAZEN

Brigham and Women's Hospital, Boston, Massachusetts

Blinded, randomized, and placebo-controlled clinical trials have established that cysteinyl leukotriene (cysLT) receptor antagonists and 5-lipoxygenase (5-LO) inhibitors are safe and effective asthma treatments. Trials of 13- to 26-wks' duration demonstrate that both the cysLT1 receptor antagonist, zafirlukast, and the 5-LO inhibitor, zileuton, improve pulmonary function and decrease daytime and nocturnal symptoms. Concomitant rescue beta -agonist inhaler use and the need for corticosteroid rescue are also reduced. Preliminary studies suggest that antileukotriene agents may also reduce indices of airway inflammation, including inflammatory cell counts and airway hyperresponsiveness. Both cysLT1 antagonists and 5-LO inhibitors offer a new approach to asthma management. Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.




This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
A. C. Henderson, E. P. Ingenito, H. Atileh, E. Israel, B. Suki, and K. R. Lutchen
Selected Contribution: How does airway inflammation modulate asthmatic airway constriction? An antigen challenge study
J Appl Physiol, August 1, 2003; 95(2): 873 - 882.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Gong Jr., W. S. Linn, S. L. Terrell, K. R. Anderson, and K. W. Clark
Anti-inflammatory and Lung Function Effects of Montelukast in Asthmatic Volunteers Exposed to Sulfur Dioxide
Chest, February 1, 2001; 119(2): 402 - 408.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
L. Xu, R. Olivenstein, J. G. Martin, and W. S. Powell
Inhaled budesonide inhibits OVA-induced airway narrowing, inflammation, and cys-LT synthesis in BN rats
J Appl Physiol, November 1, 2000; 89(5): 1852 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R G STIRLING and K F CHUNG
Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun
Thorax, October 1, 1999; 54(10): 865 - 866.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society 		  Work-Life